Drug Profile
Labetuzumab-PE40 conjugate
Alternative Names: Anti-CEA monoclonal antibody MN14-PE40 conjugate; hMN14(sFv)-PE40 immunotoxinLatest Information Update: 27 Oct 2020
Price :
$50
*
At a glance
- Originator Immunomedics
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 11 Dec 1998 New profile
- 11 Dec 1998 Preclinical development for Cancer in USA (Unknown route)